Details for Patent: 9,333,204

Which drugs does patent 9,333,204 protect, and when does it expire?

Patent 9,333,204 protects VIEKIRA XR and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 9,333,204

Title:	Solid antiviral dosage forms
Abstract:	The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Inventor(s):	Miller; Jonathan M. (Lindenhurst, ID), Morris; John B. (Grayslake, IL), Sever; Nancy E. (Northbrook, IL), Schmitt; Eric A. (Libertyville, IL), Gao; Ping X. (Highland Park, IL), Shi; Yi (Libertyville, IL), Gao; Yi (Vernon Hills, IL), Liepold; Bernd (Dossenheim, DE), Moosmann; Anna (Winterbach, DE), Pauli; Mirko (Ludwigshafen, DE), Durak; Fatih (Ludwigshafen, DE), Kessler; Thomas (Schifferstadt, DE), Hoelig; Peter A. (Waechtersbach, DE), Rosenblatt; Karin (Mannheim, DE), Kostelac; Drazen (Mannheim, DE), Gokhale; Rajeev (Singapore, SG), Costello; Mark (Chicago, IL), Knable; Carl (Elmhurst, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/677,611
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,333,204

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y			TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

International Family Members for US Patent 9,333,204

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3089757
Taiwan	201609195
World Intellectual Property Organization (WIPO)	2015103490